Clinical trials located in

Haar

Haar city is located in Germany. Currently, 6 clinical trials are being conducted in this city.

Haar, located in Bavaria, Germany, is a unique municipality near Munich. Established in 1978, it has grown into a vibrant community. Notably, Haar is home to the Eglfing-Haar psychiatric hospital, one of the largest in Bavaria, emphasizing the city’s commitment to mental health care. The city also boasts a rich cultural scene, with the Kleines Theater Haar offering a diverse program of performances. Additionally, Haar is environmentally conscious, with numerous green spaces and parks, reflecting its dedication to sustainability and quality of life for its residents.

  • CT-EU-00053507

    Study on combination therapies for Metastatic Castration-Resistant Prostate Cancer

    The clinical trial is being conducted for advanced prostate cancer, specifically metastatic castration-resistant prostate cancer. In this study, a novel drug, Pembrolizumab, is being tested in combination with other treatments. There are ten groups in the trial, each receiving a different combination of treatments, all incorporating Pembrolizumab. The primary objectives include assessing the effectiveness and safety of these treatment combinations for patients with advanced prostate cancer. Patient group allocation is based on their previous treatments, and participants may have the opportunity to restart treatments if they discontinue for reasons other than disease progression.

    • Pembrolizumab/Vibostolimab
    • Prednisone
    • Pembrolizumab
    • Dexamethasone
    • Vibostolimab
    • Olaparib
    • Enzalutamide
    • Abiraterone Acetate
    • Lenvatinib
    • Belzutifan
    • Etoposide
    • Carboplatin
    • Docetaxel
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Trial for advanced cancer treatment with pembrolizumab

    In this study, pembrolizumab (also known as MK-3475 or KEYTRUDA®) is being tested for its effectiveness in treating advanced solid tumors. These tumors are difficult to remove with surgery and may have spread to other parts of the body. The conditions include advanced cancers such as anal, bile duct, endometrial (lining of the uterus), cervical, vulvar, small cell lung cancer, mesothelioma (a rare cancer often linked to asbestos exposure), thyroid, salivary gland, neuroendocrine (hormone-producing), and colorectal (large intestine) cancers.

    Pembrolizumab is an intravenous drug designed to help the immune system recognize and attack cancer cells. In this trial, participants will be placed in one of two groups. The first group will receive pembrolizumab 200 mg every three weeks. The second group will receive pembrolizumab 400 mg every six weeks. The treatment will last for up to roughly two years.

    The purpose of the study is to evaluate the effectiveness of pembrolizumab in treating these advanced cancers and to identify any potential biomarkers that might predict which patients will benefit the most from the treatment. Participants’ responses to the therapy will be closely monitored and evaluated to determine the treatment’s impact on their conditions.

    • Pembrolizumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.